These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature. Molica S; Levato L; Mirabelli R Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717 [No Abstract] [Full Text] [Related]
8. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy. Woyach JA Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693 [No Abstract] [Full Text] [Related]
9. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603 [TBL] [Abstract][Full Text] [Related]
10. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib. Saenz-de-Viteri M; Cudrnak T Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238 [No Abstract] [Full Text] [Related]
11. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib. Poole A; Girard N; Clayton F; Tantravahi SK Leuk Lymphoma; 2017 May; 58(5):1258-1261. PubMed ID: 27750463 [No Abstract] [Full Text] [Related]
12. Rapid Multifocal Neurologic Decline in an Immunocompromised Patient. Kromm JA; Power C; Blevins G; Larratt L; van Landeghem FK; Rempel J JAMA Neurol; 2016 Feb; 73(2):226-31. PubMed ID: 26658958 [TBL] [Abstract][Full Text] [Related]
13. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib. Goldschmidt N; Rund D Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158 [No Abstract] [Full Text] [Related]
14. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Tran PN; O'Brien S Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951 [TBL] [Abstract][Full Text] [Related]
15. Is HBV prophylaxis required during CLL treatment with ibrutinib? Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112 [No Abstract] [Full Text] [Related]
16. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia. Sato R; Jacob J; Gaballa S Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253 [No Abstract] [Full Text] [Related]
17. A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus. Ramadhani P; Bramantono B; Sedana MP Acta Med Indones; 2018 Apr; 50(2):151-158. PubMed ID: 29950535 [TBL] [Abstract][Full Text] [Related]
18. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M; Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421 [TBL] [Abstract][Full Text] [Related]
19. Progressive multifocal leukoencephalopathy--a case report and review of the literature. Smolle E; Trojan A; Schuster SJ; Haybaeck J In Vivo; 2014; 28(5):941-8. PubMed ID: 25189911 [TBL] [Abstract][Full Text] [Related]
20. Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab. Ito Y; Makita S; Maeshima AM; Hatta S; Suzuki T; Yuda S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K Intern Med; 2018 Aug; 57(16):2395-2398. PubMed ID: 29526963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]